{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:49:26Z","timestamp":1793828966145,"version":"4.6.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>ABI Family Member 3 Binding Protein (ABI3BP) is an extracellular matrix protein that affects the carcinogenesis of lung and esophageal cancer. However, the relevance of ABI3BP in different forms of cancer is uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ABI3BP expression was interpreted using the Cancer Genome Atlas (TCGA) database, the Genotype Tissue Expression Atlas (GTEx) database, the Human Protein Atlas (HPA) database, the Cancer Cell Line Encyclopedia (CCLE) database, and immunohistochemistry. The R programming language was used to analyze the association between ABI3BP expression and patient prognosis and evaluate the relationship between ABI3BP and the immune characteristics of tumors. Using the GDSC and CTRP databases, a drug sensitivity analysis of ABI3BP was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ABI3BP mRNA expression was shown by differential analysis to be down-regulated in 16 tumor types relative to normal tissues, corresponding with its protein expression level as determined by immunohistochemistry. Abnormal expression of ABI3BP accurately predicts the prognosis of patients with renal chromophobe carcinoma (KICH), mesothelioma (MESO), and pancreatic adenocarcinoma (PAAD). Meanwhile, aberrant expression of ABI3BP was associated with immune checkpoints, TMB, MSI, tumor purity, HRD, LOH, and drug sensitivity. A correlation between ABI3BP expression and the amount of infiltration of several immune-related cells in pan-cancer was determined by Immune Score, Stromal Score, and Estimated Score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results show that ABI3BP might be employed as a molecular biomarker to predict prognosis, treatment susceptibility, and immunological response in patients with pan-cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1159725","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T04:29:14Z","timestamp":1682915354000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengying","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic regulation of T cell longevity and function in tumor immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-319-67577-0_4","article-title":"The role of tumor microenvironment in cancer immunotherapy","volume":"1036","author":"Frankel","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"180037","DOI":"10.1098\/rsob.180037","article-title":"Cancer immunotherapy: broadening the scope of targetable tumours","volume":"8","author":"van den Bulk","year":"2018","journal-title":"Open Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1416","article-title":"Abi3bp is a multifunctional autocrine\/paracrine factor that regulates mesenchymal stem cell biology","volume":"31","author":"Hodgkinson","year":"2013","journal-title":"Stem Cells"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s100380170049","article-title":"Cloning and sequencing of a novel human gene that encodes a putative target protein of nesh-SH3","volume":"46","author":"Matsuda","year":"2001","journal-title":"J Hum Genet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3420946","article-title":"The depletion of ABI3BP by MicroRNA-183 promotes the development of esophageal carcinoma","volume":"2020","author":"Cai","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.01.171","article-title":"Implication of p53-dependent cellular senescence related gene, TARSH in tumor suppression","volume":"380","author":"Wakoh","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"bbac558","DOI":"10.1093\/bib\/bbac558","article-title":"GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels","volume":"24","author":"Liu","year":"2023","journal-title":"Brief Bioinform"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunpaa","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discovery"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12935-019-1091-8","article-title":"Microsatellite instability: a review of what the oncologist should know","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1142\/S0219720020500274","article-title":"PESM: a novel approach of tumor purity estimation based on sample specific methylation sites","volume":"18","author":"Pang","year":"2020","journal-title":"J Bioinform Comput Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i43.6740","article-title":"Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer","volume":"11","author":"Zheng","year":"2005","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/gcc.22939","article-title":"Homologous recombination repair deficiency (HRD): from biology to clinical exploitation","volume":"60","author":"Gonzalez","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1067\/msy.2002.119306","article-title":"DNA Ploidy and its clinical implications in gastric cancer","volume":"131","author":"Baba","year":"2002","journal-title":"Surgery"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.34739","article-title":"Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications","volume":"16","author":"Zito Marino","year":"2019","journal-title":"Int J Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00652-15","article-title":"Different facets of copy number changes: permanent, transient, and adaptive","volume":"36","author":"Mishra","year":"2016","journal-title":"Mol Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"Shepard","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: then and now","volume":"16","author":"Morse","year":"2021","journal-title":"Target Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09911-9","article-title":"Small molecule inhibitors of RAS proteins with oncogenic mutations","volume":"39","author":"Orgovan","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-08-0079","article-title":"Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion","volume":"15","author":"Latini","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coph.2016.11.005","article-title":"Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment","volume":"31","author":"Gu","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12709","article-title":"The cyclin-dependent kinase inhibitor AT7519 augments cisplatin\u2019s efficacy in ovarian cancer via multiple oncogenic signaling pathways","volume":"36","author":"Wang","year":"2022","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1159725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T04:29:17Z","timestamp":1682915357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1159725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":31,"alternative-id":["10.3389\/fonc.2023.1159725"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1159725","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"article-number":"1159725"}}